Product Information
RESTASIS MULTIDOSE 0.05% EYE is a brand product labeled by Allergan, Inc., priced at $112.3176 per ML under NDC 00023530105. Its NADAC has been published 484 times since May 17, 2017.
FDA first approved this application on Dec 23, 2002. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the cyclosporine market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
.5 mg/mL
Manufacturer
Allergan, Inc.NDC
00023530105
Classification
Brand
Dosage Form
EMULSION
Route
OPHTHALMIC
Effective Date
8/19/2026
Active Ingredients
CYCLOSPORINEApproval Type
New Drug (NDA)
FDA Application
NDA050790FDA Approved
12/23/2002
TE Code
AB
On Market Since
11/10/2016
Pharmacological Classes
Price Statistics
The NADAC for RESTASIS MULTIDOSE 0.05% EYE has been published 484 times since May 17, 2017, and over the history we have for it it has risen 39.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $112.3176 per ML |
|---|---|
| All-time high | $112.6932 (Oct 12, 2022) |
| All-time low | $80.4772 (May 17, 2017) |
| 52-week high | $112.4633 |
| 52-week low | $112.3161 |
| Median price | $107.3279 |
| Average price | $104.2725 |
| Largest weekly change | +9.5% (Jan 9, 2019) |
| Weeks tracked | 484 |
| Tracking since | May 17, 2017 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the cyclosporine market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of RESTASIS MULTIDOSE 0.05% EYE?
The current National Average Drug Acquisition Cost (NADAC) for RESTASIS MULTIDOSE 0.05% EYE, manufactured by Allergan, Inc., is $112.3176 per ML (NDC 00023530105), effective Aug 19, 2026.
How has the price of RESTASIS MULTIDOSE 0.05% EYE changed over time?
Over the history we have for it, the NADAC for RESTASIS MULTIDOSE 0.05% EYE has risen 39.6%. It has been tracked across 484 weekly CMS publications since May 17, 2017.
What are the highest and lowest recorded NADAC prices for RESTASIS MULTIDOSE 0.05% EYE?
Since May 17, 2017, the NADAC for RESTASIS MULTIDOSE 0.05% EYE has ranged from a low of $80.4772 (May 17, 2017) to a high of $112.6932 (Oct 12, 2022), with a median of $107.3279 per ML.
Are there cheaper alternatives to RESTASIS MULTIDOSE 0.05% EYE?
No other NADAC-published product currently shares the active ingredient and strength of RESTASIS MULTIDOSE 0.05% EYE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures RESTASIS MULTIDOSE 0.05% EYE?
RESTASIS MULTIDOSE 0.05% EYE (NDC 00023530105) is labeled by Allergan, Inc., and CMS classifies it as a brand product.